Archive for the ‘Sgx Singapore’ Category

• Lonza Announce therapy and eclipse development and production agreement Lonza Conduct Phase 1 Production of an eclipse ET-101

  Date: 2012.04.25 | Category: Sgx Singapore | Response: 0

  
  Basel (Switzerland), California (USA) (PRWEB) March 1, 2012

  Lonza and Eclipse, announced today an agreement to manufacture Eclipse novel cancer therapeutic antibodies, ET-101, using the light of service development. ET-101 is under investigation for suppressing the growth of cancer stem cells. Under the agreement, Lonza to produce the 1st phase of clinical materials for its development and manufacturing facilities in Slough, UK.
  
  Dr. Christopher Reyes

  , CSO treatment eclipse said: “Lonzas best in class antibody production will greatly support our strategy to provide the highest quality and most effective therapies targeting cancer stem cells. Move to cell line development and further production represents an important milestone for Eclipse.

  Cancer stem cells represent a small fraction of cells in the tumor, which is believed to play an important role in the initiation of tumor recurrence and metastasis. ET-101 represents a novel therapeutic antibody designed to address these cancer stem cells. The elimination of cancer stem cells in combination with other treatments aimed at the tumor bulk, represents a new paradigm for cancer treatment, which may offer significant advantages over existing strategies and solutions for chemoresistance.

  Lonza is excited that the eclipse has chosen us to support this innovative new field of cancer therapy, said Dr. Stephan Kutzer, Chief Operating Officer, Lonza Custom Manufacturing. We are pleased to offer development services specifically designed to support new companies during the early clinical stages.

  About Eclipse
  
  Eclipse Therapeutics, Inc (Eclipse) is a privately held biotechnology company dedicated to discovering and developing therapies that target cancer stem cells and other forms of innovative cancer treatments. Cancer stem cells are a subset of cells in the tumor is thought to play an important role in the initiation of tumor recurrence and metastasis. They also participated in the resistance to the current standard cancer care. Eclipse uses its deep knowledge in the cancer stem cell biology and therapeutic antibodies for the development of new therapies designed to treat the unmet needs of cancer patients. For more information, please visit http://www.eclipsetherapeutics.com.

  
  About Lonza

  
  Lonza is one of the world’s leading suppliers to the pharmaceutical, healthcare and life sciences industry. Products and services cover the needs of its customers from research to final product manufacture. It is a world leader in the manufacture and support of active pharmaceutical ingredients both chemically as well as biotechnology. Biopharmaceuticals is a key factor in the growth of the pharmaceutical and biotechnology industries. Lonza has strong capabilities in large and small molecules, peptides, amino acids and niche bioproducts which play an important role in the development of new drugs and medical products. Lonza
  
  is also a world leader in providing innovative control microbiological, chemical and related decision to selectively kill or inhibit the growth of harmful microorganisms. Its activities cover the field of water treatment, personal care, health and hygiene, industrial, conservation, protection of materials and wood processing. In addition, Lonza is a leader in the field of cellular research, endotoxin detection and cell therapy manufacturing. In addition, the company is a leading provider of value chemical and biotech ingredients to food and agricultural markets.

  Lonza is headquartered in Basel, Switzerland, and listed on the Swiss Stock Exchange and secondary listing on the Singapore Exchange Securities Trading Limited (SGX-ST). Lonza is not subject to the requirements of SGX-ST permanent list. Lonza depends on the rules listed on the Swiss Stock Exchange, with no specific requirements equivalent to the listing rules of SGX-ST for the interested person transactions, acquisitions and sales, and delisting. In 2011 the company was selling CHF 2.69 billion. Further information can be found at http://www.lonza.com.

  # # #

  clear = “all”

• IIFL (India Line) Select OrangeScape PaaS for business process automation

  Date: 2012.04.01 | Category: Sgx Singapore | Response: 0

  
  Chennai, India (PRWEB) March 12, 2012

  IIFL has a large distributed workforce across the country that need to cooperate on a range of business processes across organizational boundaries. Many of these business processes are unique and differentiated business IIFLs. By choosing OrangeScape, IIFL used without the cloud application development tools for the automation of long-tailed business applications. IIFL out in solving this problem with the use of long-tailed application of homogeneous clouds and the native platform approach using OrangeScape platform. OrangeScape Visual PaaS, with its patented engine rule, visual forms and workflow designer helps IIFL to build business applications rapidly deploy and scale easily on Google App Engine.

  CIO IIFL, Sankarson Banerjee said IIFL is 15,000 + members, and the need for flexibility and innovation is very high to very quickly respond to dynamic market conditions. We are looking for a platform that we can develop and not a static solution, since our problems are constantly evolving. We evaluated the various options and select the Visual OrangeScape PaaS for his maturity and ability to develop large programs, work processes of the enterprise. It promises to build a flexible and often change rapidly, while at the same time allows a cost-effective and rapid deployment. It is important to us as users of Google applications, OrangeScape, fits well into Google in the cloud with Google App Engine and is working with our environment, Google Apps

  
  General Director and founder of OrangeScape

  Suresh Sambandam said OrangeScape Visual PaaS leads business innovation through simplification of application development company. IIFL is not only the name of the contents of a house in the financial services industry / stock traders, but they are also very big Google Apps users in this part of the world. This once again confirms the importance of major customers OrangeScapes Google Apps enterprise. We are pleased that IIFL among our customers.

  
  About

  IIFL
  
  IIFL (India line) group, is one of the leading players in the Indian financial services space. IIFL offers advice and execution platform for a range of financial services covering products ranging from stocks and derivative products, asset management, asset management, insurance, term deposits, loans, investment banking, Indian government bonds and other small savings instruments. IIFL has recently received permission in principle for securities trading and clearing membership of the Singapore Exchange (SGX) opens the way for IIFL become the first Indian brokerage to obtain membership in the SGX. For more information, please visit: http://www.indiainfoline.com/Aboutus

  About OrangeScape
  
  OrangeScape rare breed of technology company, founded in 2003 with customers and partners in the United States, India, UK and Europe. OrangeScape is one of 10 Global cloud platform-as-service providers is shown in the PaaS reports Gartner and Forrester. OrangeScape provides a simulation-driven visual development environment for creating business applications and can be deployed at major public cloud platforms like Google App Engine, or private cloud environments. OrangeScape is a list of clients includes the allocation of Unilever, Citibank, Pfizer, AstraZeneca, Sterlite, Fullerton, Geojit and other large enterprises. For more information, please visit: http://www.orangescape.com

  clear = “all”